NVZMF (Novonesis (Novozymes) B) Other Long-Term Liabilities: $178 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
90 GF Score
Price $66.50
GF Value $64.31
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Other Long-Term Liabilities?

Novonesis (Novozymes) B NVZMF +1.01% 90 Other Long-Term Liabilities is $178 Mil as of Jun. 2026. GuruFocus rates NVZMF with a GF Score™ of 90/100 and a GF Value™ of $64.31 (Fairly Valued). The stock has 5 warning signs investors should review.

Novonesis (Novozymes) B's other long-term liabilities for the quarter that ended in Jun. 2026 was $178 Mil.

Novonesis (Novozymes) B's quarterly other long-term liabilities increased from Dec. 2025 ($156 Mil) to Mar. 2026 ($166 Mil) and increased from Mar. 2026 ($166 Mil) to Jun. 2026 ($178 Mil).

Novonesis (Novozymes) B's annual other long-term liabilities increased from Dec. 2023 ($37 Mil) to Dec. 2024 ($150 Mil) and increased from Dec. 2024 ($150 Mil) to Dec. 2025 ($156 Mil).

Novonesis (Novozymes) B Other Long-Term Liabilities Related Terms

Novonesis (Novozymes) B Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Other Long-Term Liabilities Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.49 176.81 37.34 150.15 155.73

Novonesis (Novozymes) B Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.68 171.08 155.73 165.57 178.35
NVZMF
90GF Score
Novonesis (Novozymes) B NVZMF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $178 Mil mean?
Novonesis (Novozymes) B (NVZMF) has a Other Long-Term Liabilities of $178 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Other Long-Term Liabilities too high?
Novonesis (Novozymes) B's current Other Long-Term Liabilities is $178 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Other Long-Term Liabilities compare to LIN and SHW?
Novonesis (Novozymes) B's Other Long-Term Liabilities of $178 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Chemicals company?
A good Other Long-Term Liabilities depends on the Chemicals industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Other Long-Term Liabilities is $178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $64.31, compared to a current price of $66.50 — trading 3.4% above its estimated fair value. The current Other Long-Term Liabilities is $178 Mil. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Other Long-Term Liabilities is $178 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $66.50 is trading 3.4% above its estimated GF Value™ of $64.31. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Other Long-Term Liabilities: $178 Mil
  • GF Value™: $64.31 vs. price of $66.50 (3.4% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score

Get the complete analysis for NVZMF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.50
Price
$64.31
GF Value